SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Hoechst (HOE)
HMR 1.280-1.5%3:56 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Teddy who wrote (15)5/15/1998 8:44:00 AM
From: Teddy   of 42
 
This is way cool:

i found this from a smart guy:

Did some research on leflunomide, the drug that Hoechst filed a NDA with the FDA. It has a very novel mechanism of action that potentially makes it useful in rheumatologic diseases like lupus, rheumatoid arthritis, is considered one of the disease modifying drugs for rheumatoid arthritis.
The interesting thing, I believe is that there are a lot of research groups using this drug in transplantation of different organs, with very promising results. It prevents rejection of organs transplanted between different species: ie: a rat heart to a mouse (or viceversa, I am not sure).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News